Navigation Links
PharmAthene Reports First Quarter 2011 Financial and Operating Results
Date:5/11/2011

er the Company's SparVax™ program and the completion of patient dosing in the Phase I Valortim® dose escalation clinical trial, partially offset by the decrease in development expenses related to the Protexia® bioscavenger program, which was completed in 2010.

General and administrative expenses for the Company were $4.9 million and $5.3 million for the quarters ended March 31, 2011 and 2010, respectively.  The decrease in general and administrative expense during the most recent period resulted from cost reductions implemented during 2010 and a reduction in bad debt expense, partially offset by an increase in legal costs associated with the trial in the case against SIGA.

For the first quarter of 2011 PharmAthene's net loss attributable to common shareholders was $2.1 million, or $0.04 per share, compared to $7.9 million, or $0.28 per share, in the same period of 2010.  The year-over-year decrease in net loss includes the impact of the change in fair value of the Company's derivative instruments, which was $2.5 million for the three months ended March 31, 2011 compared to $0.3 million for the three months ended March 31, 2010. The decrease in fair value, which became a source of other income, was primarily associated with a decrease in PharmAthene's stock price from December 31, 2010 to March 31, 2011.

As of March 31, 2011, the Company had cash and cash equivalents, short-term investments, and net U.S. government accounts receivables and other receivables, including unbilled receivables, totaling approximately $18.7 million compared to $21.6 million at December 31, 2010.  The decrease at March 31, 2011 was primarily attributable to the net impact of cash used to fund operations.

"We continued to make steady progress in the first quarter of 2011 and achieved important program milestones," remarked Eric I. Richman, President and Chief Executive Officer. "We achieved several technical milestones with respect
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related biology technology :

1. PharmAthene to Host Year-End 2010 Earnings Conference Call and Webcast on Monday, March 28, 2011
2. PharmAthene Strengthens Scientific Leadership and Program Management for Future Growth
3. PharmAthene Receives FDA Clearance to Reinitiate Clinical Testing of Valortim®
4. PharmAthene Reports Third Quarter 2010 Financial and Operational Results
5. PharmAthene Receives Four Therapeutic Discovery Project Grants Totaling Approximately $850,000
6. PharmAthene Announces Pricing of $15 Million Public Offering
7. PharmAthene Announces Proposed Common Stock Offering
8. PharmAthene Announces $3.9 Million Registered Direct Offering
9. PharmAthene CEO To Participate on Biosecurity Panel at the 2010 BIO International Conference
10. PharmAthene Appoints Mitchel Sayare, Ph.D. to the Companys Board of Directors
11. PharmAthene Reports Year-End 2009 Financial and Operational Results and Provides Update On Ongoing Litigation With SIGA Technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... Korea , May 23, 2013 ... SillaJen, Inc., a private biotherapeutics and contract research ... biological products for cancer, announced today a publication ... patients treated with the oncolytic and immunotherapeutic vaccinia ... This research was published in the May 15 ...
(Date:5/23/2013)... Bed bugs compromised Penn State. A ... it. Meanwhile, My Cleaning Products offered complimentary samples of its ... pests without using harmful chemical elements. , Based on ... affected building was actually a dormitory , My Cleaning ... on May 13 and bed bug presence was confirmed on ...
(Date:5/22/2013)... PA (PRWEB) May 22, 2013 Oven ... with the integrated potentiometers or via a PC ... design measuring two and one half inches square can ... a zero voltage switched, low noise solid state relay. ... power isolation for the communication port and sensor input. ...
(Date:5/22/2013)... The Conference Forum announced the launch ... Trials conference taking place on September 19-20 at the ... Disruptive thinkers from Novartis, Pfizer, Eli Lilly, Shire, Medimmune, ... reduce expensive infrastructure, engage patients and generate credible clinical ... or novel, or it must change the very nature ...
Breaking Biology Technology:Pusan National University Announces Science Translational Medicine Publication Highlighting Landmark Demonstration of Functional Anti-Cancer Antibody Induction in Patients Following JX-594 Treatment 2Pusan National University Announces Science Translational Medicine Publication Highlighting Landmark Demonstration of Functional Anti-Cancer Antibody Induction in Patients Following JX-594 Treatment 3Penn State Dorm Infested with Bed Bugs, My Cleaning Products Offers Complimentary Sample of Bed Bug Spray to Help Bed Bug Victims 2New AC Temperature Controller Announced by Oven Industries 2Disruptive Innovation Hits Clinical Trials, Dedicated Event Launches 2
... , ... Kuantan, Malaysia facility awarded ISO13485 medical manufacturing certification. , ... Weybridge, United Kingdom (PRWEB) January ... today that its manufacturing facility in Kuantan, Malaysia has received ISO 13485:2003 medical ...
... , WASHINGTON , Jan. 22 The Advisory Board ... conference call hosted by Robert W. Musslewhite , Chief Executive Officer ... Company,s financial results for the quarter ended December 31, 2009 . ... at 6:00 p.m., Eastern Time .  The Company plans to release ...
... , , Twenty leading US ... the benefits of NIH funding through the 2009 Recovery and ... In advance of the one-year anniversary of the ... twenty of the nation,s leading research institutions, patient advocates and ...
Cached Biology Technology:All TT Electronics Integrated Manufacturing Services Facilities Accredited with Medical Manufacturing Standard 2The Advisory Board Company Schedules Third Quarter Conference Call for February 4, 2010 2A Recovery Act Success Story: NIH Funding of Biomedical Innovation Is Creating Jobs, Fueling Industry Growth, and Helping Reduce Long-term Health Care Costs 2A Recovery Act Success Story: NIH Funding of Biomedical Innovation Is Creating Jobs, Fueling Industry Growth, and Helping Reduce Long-term Health Care Costs 3
(Date:5/23/2013)... Bochum,s medics have succeeded in treating cerebral palsy with ... brain damage, a 2.5 year old boy had been ... of survival. Just two months after treatment with the ... over the following months, the child learned to speak ... those from a Korean study, dispel the long-held doubts ...
(Date:5/23/2013)... Neuron , the team reveal the interplay of ... funded by the Wellcome Trust and BBSRC. , ... we improve our perceptual abilities. While these changes can ... also affect the fidelity of that response. ... explains: "When you communicate with others, you can make ...
(Date:5/22/2013)... conclude that the 20 percent reduction in lung ... chest X-ray (CXR) screening previously reported in the ... centers in the United States. , Philadelphia, PAPhysicians ... about the benefits and risks of LDCT lung ... New England Journal of Medicine of the ...
Breaking Biology News(10 mins):First successful treatment of pediatric cerebral palsy with autologous cord blood 2NLST: CT detects twice as many lung cancers as X-ray at initial screening exam 2NLST: CT detects twice as many lung cancers as X-ray at initial screening exam 3
... only to be central to the process that causes ... muting the high from methamphetamine and other addictive drugs. ... cation transporter 3 or oct3, fills a longstanding gap ... symptoms like tremor, stiffness, slowness of movement and postural ...
... Wash. -- Researchers have detected common plant toxins that ... fires. The results from the new study also suggest ... - a reason to keep human exposures to a ... -- known as alkaloids -- helps researchers understand how ...
... scientists from Cornell University have developed a new tool ... the origins of specific gene mutations. This research, published ... ( http://www.genetics.org ), helps shed light on times ... helps scientists close in on gene mutations that make ...
Cached Biology News:Brain protein central to both Parkinson's, drug addiction identified 2Brain protein central to both Parkinson's, drug addiction identified 3Brain protein central to both Parkinson's, drug addiction identified 4Potentially harmful chemicals found in forest fire smoke 2Tiny differences in our genes help shed light on the big picture of human history 2